Bayer Cash Flow from Investing Activities 2012-2026 | BAYRY
Bayer annual/quarterly cash flow from investing activities history and growth rate from 2012 to 2026. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Bayer cash flow from investing activities for the quarter ending March 31, 2026 was $0.328B, a 93.21% increase year-over-year.
- Bayer cash flow from investing activities for the twelve months ending March 31, 2026 was $-1.631B, a 209.66% increase year-over-year.
- Bayer annual cash flow from investing activities for 2025 was $-1.437B, a 909.67% decline from 2024.
- Bayer annual cash flow from investing activities for 2024 was $0.177B, a 104.66% decline from 2023.
- Bayer annual cash flow from investing activities for 2023 was $-3.806B, a 51.73% increase from 2022.
|
Bayer Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2025 | $-1,437 |
| 2024 | $177 |
| 2023 | $-3,806 |
| 2022 | $-2,509 |
| 2021 | $1,012 |
| 2020 | $-4,653 |
| 2019 | $-752 |
| 2018 | $-40,334 |
| 2017 | $-488 |
| 2016 | $-9,660 |
| 2015 | $-3,067 |
| 2014 | $-20,656 |
| 2013 | $-3,428 |
| 2012 | $-1,052 |
| 2011 | $-5,418 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |